Top

Clinical Orthopaedics and Related Research®

Published in:

01-12-2009 | Symposium: Tribute to Dr. Marshall Urist: Musculoskeletal Growth Factors

Alendronate Enhances Osteogenic Differentiation of Bone Marrow Stromal Cells: A Preliminary Study

Authors: Hyung Keun Kim, PhD, Ji Hyun Kim, MS, Azlina Amir Abbas, MS (Ortho), Taek Rim Yoon, MD

Published in: Clinical Orthopaedics and Related Research® | Issue 12/2009

Abstract

Alendronate inhibits osteoclastic activity. However, some studies suggest alendronate also has effects on osteoblast activity. We hypothesized alendronate would enhance osteoblastic differentiation without causing cytotoxicity of the osteoblasts. We evaluated the effect of alendronate on the osteogenic differentiation of mouse mesenchymal stem cells. D1 cells (multipotent mouse mesenchymal stem cells) were cultured in osteogenic differentiation medium for 7 days and then treated with alendronate for 2 days before being subjected to various tests using MTT assays, Alizarin Red, enzyme-linked immunosorbent assay, energy-dispersive xray spectrophotometry, reverse transcriptase–polymerase chain reaction, confocal microscopy, and flow cytometric analysis. D1 cells differentiated into osteoblasts in the presence of osteogenic differentiation medium as confirmed by positive Alizarin Red S staining, increased alkaline phosphatase activity and osteocalcin mRNA expression, a calcium peak by energy-dispersive xray spectrophotometry, and by positive immunofluorescence staining against CD44. Osteogenic differentiation was enhanced after treatment with alendronate as confirmed by Alizarin Red S staining, elevated alkaline phosphatase activity and osteocalcin mRNA expression, a greater calcium peak by energy-dispersive xray spectrophotometry, and by immunofluorescence staining against CD44 by flow cytometric analysis. These data suggest alendronate enhances osteogenic differentiation when treated with mouse mesenchymal stem cells in osteogenic differentiation medium.

Adamia S, Maxwell CA, Pilarski LM. Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:3–14.CrossRefPubMed

Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535–1541.CrossRefPubMed

Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189–1199.CrossRefPubMed

Boonekamp PM, van der Wee-Pals LJ, van Wijk-van Lennep MM, Thesing CW, Bijvoet OL. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner. 1986;1:27–39.PubMed

Chen CH, Ho ML, Chang JK, Hung SH, Wang GJ. Green tea catechin enhances osteogenesis in a bone marrow mesenchymal stem cell line. Osteoporos Int. 2005;16:2039–2045.CrossRefPubMed

Conlan MJ, Rapley JW, Cobb CM. Biostimulation of wound healing by low-energy laser irradiation. J Clin Periodontol. 1996;23:492–496.CrossRefPubMed

Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077–2082.CrossRefPubMed

Dahir GA, Cui Q, Anderson P, Simon C, Joyner C, Triffitt JT, Balian G. Pluripotential mesenchymal cells repopulate bone marrow and retain osteogenic properties. Clin Orthop Relat Res. 2000;379(suppl):S134–S145.CrossRefPubMed

Delos D, Yang X, Ricciardi BF, Myers ER, Bostrom MP, Camacho NP. The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta. J Orthop Res. 2008;26:153–164.CrossRefPubMed

10.

Dvorak MM, Siddiqua A, Ward DT, Carter DH, Dallas SL, Nemeth EF, Riccardi D. Physiological changes in extracellular calcium concentration directly control osteoblast function in the absence of calciotropic hormones. Proc Natl Acad Sci USA. 2004;101:5140–5145.CrossRefPubMed

11.

Evans CE, Braidman IP. Effects of two novel bisphosphonates on bone cells in vitro. Bone Miner. 1994;26:95–107.CrossRefPubMed

12.

Fast DK, Felix R, Dowse C, Neuman WF, Fleisch H. The effects of diphosphonates on the growth and glycolysis of connective tissue cells in culture. Biochem J. 1978;172:97–107.PubMed

13.

Felix R, Guenther HL, Fleisch H. The subcellular distribution of [14C]dichloromethylene bisphosphonate and [14C]1-hydroxyethylidene-1,1-bisphosphonate in cultured calvaria cells. Calcif Tissue Int. 1984;36:108–113.CrossRefPubMed

14.

Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA. Alendronate mechanism of action: geranylgeraniol, an intermediate in the melavonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA. 1999;96:133–138.CrossRefPubMed

15.

Fromigue O, Body JJ. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest. 2002;25:539–546.PubMed

16.

Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G. Biphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone. 1998;22:455–461.CrossRefPubMed

17.

Gundberg CM, Hauschka PV, Lian JB, Gallop PM. Osteocalcin: isolation, characterization, and detection. Methods Enzymol. 1984;107:516–544.CrossRefPubMed

18.

Hughes DE, MacDonald BR, Russell RG, Growen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest. 1989;83:1930–1935.CrossRefPubMed

19.

Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995;10:1478–1487.PubMedCrossRef

20.

Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials. 2004;25:4105–4115.CrossRefPubMed

21.

Jamal HH, Aubin JE. CD44 Expression in fetal rat bone: in vivo and in vitro analysis. Exp Cell Res. 1996;223:467–477.CrossRefPubMed

22.

Karu T. High-tech helps to estimate cellular mechanisms of low power laser therapy. Lasers Surg Med. 2004;34:298–299.CrossRefPubMed

23.

Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13:581–589.CrossRefPubMed

24.

Mackie PS, Fisher JL, Zhou H, Choong PF. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer. 2001;84:951–958.CrossRefPubMed

25.

Mathov I, Plotkin LI, Sgarlata CL, Leoni J, Bellido T. Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro. J Bone Miner Res. 2001;16:2050–2056.CrossRefPubMed

26.

Mester E, Jaszsagi-Nagy E. The effects of laser radiation on wound healing and collagen synthesis. Studia Biophys. 1973;35:227–230.

27.

Naidu A, Dechow PC, Spears R, Wright JM, Kessler HP, Opperman LA. The effects of bisphosphonates on osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106:829–837.CrossRef

28.

Oron U, Yaakobi T, Oron A, Hayam G, Gepstein L, Rubin O, Wolf T, Ben Haim S. Attenuation of infarct size in rats and dogs after myocardial infarction by low-energy laser irradiation. Laser Surg Med. 2001;28:204–211.CrossRef

29.

Otsuru S, Tamai K, Yamazaki T, Yoshikawa H, Kaneda Y. Circulating bone marrow-derived osteoblast progenitor cells are recruited to the bone-forming site by the CXCR4/stromal cell-derived factor-1 pathway. Stem Cells. 2008;26:223–234.CrossRefPubMed

30.

Owen TA, Holthuis J, Markose E, van Wijnen AJ, Wolfe SA, Grimes SR, Lian JB, Stein GS. Modifications of protein-DNA interactions in the proximal promoter of a cell-growth-regulated histone gene during onset and progression of osteoblast differentiation. Proc Natl Acad Sci USA. 1990;87:5129–5133.CrossRefPubMed

31.

Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–147.CrossRefPubMed

32.

Plasmans CM, Jap PH, Kuijpers W, Slooff TJ. Influence of a diphosphonate on the cellular aspect of young bone tissue. Calcif Tissue Int. 1980;32:247–266.CrossRefPubMed

33.

Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104:1363–1374.CrossRefPubMed

34.

Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res. 2000;60:6001–6007.PubMed

35.

Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996;97:2692–2696.CrossRefPubMed

36.

Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991;88:2095–2105.CrossRefPubMed

37.

Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, Leu CT, Huang Z, Ramachandaran C, Rodan SB, Rodan GA. Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc Nat Acad Sci USA. 1996;93:3068–3073.CrossRefPubMed

38.

Shanbhag AS. Use of bisphosphonates to improve the durability of total joint replacements. J Am Acad Orthop Surg. 2006;14:215–225.PubMed

39.

Sikavitsas VI, Temenoff JS, Mikos AG. Biomaterial and bone mechanotransduction. Biomaterials. 2001;22:2581–2593.CrossRefPubMed

40.

van Beek E, Lowik C, van der Pluijm G, Papapoulos S. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res. 1999;14:722–729.CrossRef

41.

von Knoch F, Jaquiery C, Kowalsky M, Schaeren S, Alabre C, Martin I, Rubash HE, Shanbhag AS. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials. 2005;26:6941–6949.CrossRef

Title: Alendronate Enhances Osteogenic Differentiation of Bone Marrow Stromal Cells: A Preliminary Study
Authors: Hyung Keun Kim, PhD
Ji Hyun Kim, MS
Azlina Amir Abbas, MS (Ortho)
Taek Rim Yoon, MD
Publication date: 01-12-2009
Publisher: Springer-Verlag
Published in: Clinical Orthopaedics and Related Research® / Issue 12/2009
Print ISSN: 0009-921X
Electronic ISSN: 1528-1132
DOI: https://doi.org/10.1007/s11999-008-0409-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Alendronate Enhances Osteogenic Differentiation of Bone Marrow Stromal Cells: A Preliminary Study

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2009

Femoral Head Size and Wear of Highly Cross-linked Polyethylene at 5 to 8 Years

Acknowledgment to Reviewers

Are Endogenous BMPs Necessary for Bone Healing during Distraction Osteogenesis?

The Classic: A Morphogenetic Matrix for Differentiation of Cartilage in Tissue Culture

The Classic: A Morphogenetic Matrix for Differentiation of Bone Tissue

Prophylaxis of Heterotopic Ossification of the Hip: Systematic Review and Meta-Analysis